Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 192, Issue 6, Pages 1047-1051Publisher
OXFORD UNIV PRESS INC
DOI: 10.1086/432731
Keywords
-
Categories
Funding
- NIAID NIH HHS [P01AI056013] Funding Source: Medline
Ask authors/readers for more resources
Successful postexposure treatment for inhalation anthrax is thought to include neutralization of anthrax toxin. The soluble anthrax toxin receptor/tumor endothelial marker 8 and capillary morphogenesis protein 2 (sATR/TEM8 and sCMG2, respectively) receptor decoys bind to anthrax toxin protective antigen (PA) and compete with cellular receptors for binding. Here, we show that, in a tissue-culture model of intoxication, sCMG2 is a 11.4-fold more potent antitoxin than sATR/TEM8 and that this increased activity corresponds to an similar to 1000- fold higher PA-binding affinity. Stoichiometric concentrations of sCMG2 protect rats against lethal toxin challenge, making sCMG2 one of the most effective anthrax antitoxins described to date.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available